“Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV after Hemopoietic Stem Cell Transplantation (HSCT).”, in American Society of Hematology 52nd Annual Meeting and Exposition, Orlando, Fl, 2010.
, “Acute Graft-Versus-Host Disease Biomarkers Measured During Therapy Can Predict Treatment Outcomes: A Blood and Marrow Transplant Clinical Trials Network Study”, Blood, vol. 119, pp. 3854-3860, 2012.
, “Prevalence of Persistent Pain 3 to 5 Years Post Primary Root Canal Therapy and its Impact on Oral Health-Related Quality of Life: PEARL Network Findings”, J Endod, vol. 40, pp. 1917-1921, 2014.
, “Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO)”, presented at the 2008, Fort Lauderdale, FL, 2008.
, , “Clinical trials referral resource. Clinical trials with PSC-833”, Oncology, vol. 11, pp. 490-3, 1997.
, “Lessons from IAVI-006, a Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the PTHR.HIVA DNA and MVA.HIVA Vaccines in a Prime-Boost Strategy to Induce HIV-1 Specific T-Cell Responses in Healthy Volunteers”, Vaccine, vol. 26, pp. 6671-6677, 2008.
, “Clinical trials referral resource. Clinical trials in elderly patients.”, Oncology, vol. 11, pp. 838-44, 1997.
, “Retrospective Studies: A Fresh Look.”, Am J Speech Lang Pathol, vol. 25, no. 2, pp. 157-63, 2016.
, “Evaluation of the Mercy TAPE: Performance Against the Standard for Pediatric Weight”, Ann Emerg Med, vol. 62, pp. 332-339.e6, 2013.
, “Evaluation of the Mercy TAPE: performance against the standard for pediatric weight estimation.”, Ann Emerg Med, vol. 62, no. 4, pp. 332-339.e6, 2013.
, “Validation and human factor analysis study of an infant weight estimation device.”, BMC Pediatr, vol. 20, no. 1, p. 30, 2020.
, “Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study”, in American Society of Hematology (ASH), 2020.
, “Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study”, Blood Adv, vol. 7, no. 14, pp. 3506-3515, 2023.
, “Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study”, in 62nd ASH Annual Meeting and Exposition, 2020.
, “Clinical trials referral resource. Current phase III, NCI-supported, Cooperative Group Clinical Trials in breast cancer.”, Oncology (Williston Park), vol. 18, no. 4, pp. 463-4, 467-8, 470, 2004.
, “Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.”, J Clin Oncol, vol. 13, no. 8, pp. 2056-65, 1995.
, “Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer.”, J Natl Cancer Inst, vol. 87, no. 24, pp. 1837-45, 1995.
, “Paclitaxel Activity in Heavily Pretreated Breast Cancer: A National Cancer Institute Treatment Referral Center Trial”, J Clin Oncol, vol. 13, pp. 2056-2065, 1995.
, “Current Cooperative Group phase III clinical trials in early stage breast cancer”, Oncology, vol. 15, pp. 52-56, 2001.
, “Clinical trials referral resource. Current cooperative group phase III clinical trials in early-stage breast cancer.”, Oncology (Williston Park), vol. 15, no. 2, pp. 176-7, 181-2, 185, 2001.
, “Meeting Highlights: A Reappraisal of Research Results For the Local Treatment of Early Stage Breast Cancer”, J Natl Cancer Inst, vol. 87, pp. 1837-1845, 1995.
, ,